Twist Bioscience Co. (NASDAQ:TWST) insider Patrick John Finn sold 2,702 shares of Twist Bioscience stock in a transaction on Monday, April 5th. The shares were sold at an average price of $126.72, for a total transaction of $342,397.44. Following the completion of the sale, the insider now directly owns 43,102 shares in the company, valued at approximately $5,461,885.44. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website.
Shares of NASDAQ TWST opened at $127.64 on Thursday. The firm has a 50-day simple moving average of $131.27 and a 200-day simple moving average of $127.75. The stock has a market capitalization of $6.21 billion, a price-to-earnings ratio of -34.04 and a beta of 0.83. Twist Bioscience Co. has a 52 week low of $25.72 and a 52 week high of $214.07.
Twist Bioscience (NASDAQ:TWST) last released its quarterly earnings results on Wednesday, February 3rd. The company reported ($0.72) EPS for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.74) by $0.02. The firm had revenue of $28.16 million for the quarter, compared to analyst estimates of $25.26 million. Twist Bioscience had a negative net margin of 155.31% and a negative return on equity of 44.62%. Equities research analysts expect that Twist Bioscience Co. will post -3.03 earnings per share for the current fiscal year.
Several hedge funds and other institutional investors have recently added to or reduced their stakes in TWST. BlackRock Inc. increased its position in shares of Twist Bioscience by 11.8% during the 4th quarter. BlackRock Inc. now owns 3,499,004 shares of the company’s stock worth $494,375,000 after purchasing an additional 370,176 shares during the last quarter. Sumitomo Mitsui Trust Holdings Inc. increased its holdings in Twist Bioscience by 14.5% in the 4th quarter. Sumitomo Mitsui Trust Holdings Inc. now owns 1,850,717 shares of the company’s stock valued at $261,488,000 after purchasing an additional 234,339 shares during the last quarter. Nikko Asset Management Americas Inc. raised its position in Twist Bioscience by 13.9% in the fourth quarter. Nikko Asset Management Americas Inc. now owns 1,840,306 shares of the company’s stock valued at $260,017,000 after purchasing an additional 223,928 shares during the period. Price T Rowe Associates Inc. MD boosted its position in shares of Twist Bioscience by 48.5% during the fourth quarter. Price T Rowe Associates Inc. MD now owns 970,977 shares of the company’s stock worth $137,189,000 after buying an additional 317,301 shares during the period. Finally, Credit Suisse AG grew its stake in shares of Twist Bioscience by 1,743.6% in the fourth quarter. Credit Suisse AG now owns 846,581 shares of the company’s stock valued at $119,613,000 after buying an additional 800,661 shares in the last quarter. Institutional investors and hedge funds own 87.90% of the company’s stock.
Twist Bioscience Company Profile
Twist Bioscience Corporation, a synthetic biology company, manufactures and sells synthetic DNA-based products. The company's DNA synthesis platform enables the manufacturing of synthetic DNA by writing DNA on a silicon chip. It offers synthetic DNA-based products, including synthetic genes, tools for sample preparation, antibody libraries for drug discovery and development, and DNA as a digital data storage medium.
Featured Article: Using other technical indicators with support levels
Receive News & Ratings for Twist Bioscience Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Twist Bioscience and related companies with MarketBeat.com's FREE daily email newsletter.